Bring It On Home

FDA Shocker: Unpacking the Controversial Drug Approval Rejection

46 min · 9. juni 2024
episode FDA Shocker: Unpacking the Controversial Drug Approval Rejection cover

Beskrivelse

Join Daniel and Cody as they dive into the shocking news from the FDA's advisory committee review. We'll set the stage with an in-depth look at the independent panels of researchers, insurance executives, and doctors who play a crucial role in drug approval. Discover why the MAPS program, integrating psychotherapy with new drug trials, has turned the review process upside down. They'll discuss the controversies, including trial design issues, racial disparities among participants, and the surprising rejection of a breakthrough PTSD treatment. Is there a deeper bias within the FDA, or is it a matter of incompetence from the drug development team at Lycos Therapeutics?  Explore the impact on veterans and PTSD survivors, the future of therapies like MDMA and ketamine, and how companies like Healing Realty Trust are navigating these turbulent waters. Tune in for a critical analysis and personal opinions on the FDA's decision, its implications for mental health treatment, and what it means for the future of drug development and approval.

Kommentarer

0

Vær den første til å kommentere

Registrer deg nå og bli medlem av Bring It On Home sitt community!

Kom i gang

2 Måneder for 19 kr

Deretter 99 kr / Måned · Avslutt når som helst.

  • Eksklusive podkaster
  • 20 timer lydbøker i måneden
  • Gratis podkaster

Alle episoder

24 Episoder

episode Ep. 25 - NAD, Psychedelics, and New Frontiers in Therapy cover

Ep. 25 - NAD, Psychedelics, and New Frontiers in Therapy

Join us as we dive into a conversation about the benefits of NAD, the importance of clean living, and the emerging role of psychedelics in therapy. Our host shares his personal journey of going 60 days clean and the transformative effects of NAD on his physical performance. We also explore the latest news on MDMA-assisted therapy for PTSD, including congressional support and the need for proper training and planning. From the potential of psychedelic retreats to the importance of therapist-patient relationships in psychedelic therapy, this episode covers a range of topics at the intersection of wellness, mental health, and innovative treatments. Tune in to learn about the latest advancements and hear firsthand experiences that could shape the future of health and wellness.

18. juni 202435 min
episode FDA Shocker: Unpacking the Controversial Drug Approval Rejection cover

FDA Shocker: Unpacking the Controversial Drug Approval Rejection

Join Daniel and Cody as they dive into the shocking news from the FDA's advisory committee review. We'll set the stage with an in-depth look at the independent panels of researchers, insurance executives, and doctors who play a crucial role in drug approval. Discover why the MAPS program, integrating psychotherapy with new drug trials, has turned the review process upside down. They'll discuss the controversies, including trial design issues, racial disparities among participants, and the surprising rejection of a breakthrough PTSD treatment. Is there a deeper bias within the FDA, or is it a matter of incompetence from the drug development team at Lycos Therapeutics?  Explore the impact on veterans and PTSD survivors, the future of therapies like MDMA and ketamine, and how companies like Healing Realty Trust are navigating these turbulent waters. Tune in for a critical analysis and personal opinions on the FDA's decision, its implications for mental health treatment, and what it means for the future of drug development and approval.

9. juni 202446 min